Activation of the PI3K/AKT pathway may not solely explain the lack of effectiveness of palbociclib in LBC, and other factors may drive resistance to Palbociclib [30]. Here, AKT1 is linked to CDH1-related diffuse gastric and lobular breast cancer syndrome.